Clinical management of cutaneous adverse events in patients on targeted anticancer therapies and immunotherapies : a national consensus statement by the Spanish Academy of Dermatology and Venereology and the Spanish Society of Medical Oncology
Grávalos, Cristina (Hospital Universitario 12 de Octubre (Madrid))
Sanmartín, O. (Fundació Institut Valencià d'Oncologia)
Gúrpide, A. (Clínica Universidad de Navarra)
España, A. (Clínica Universidad de Navarra)
Majem, Margarita (Institut d'Investigació Biomèdica Sant Pau)
Suh Oh, H.J. (Complejo Hospitalario Universitario de Pontevedra)
Aragón, I. (Complejo Hospitalario Universitario de Huelva)
Segura, S. (Hospital del Mar (Barcelona, Catalunya))
Beato, C. (Hospital Universitario Virgen Macarena (Sevilla, Andalusia))
Botella, R. (Instituto de Investigación Sanitaria La Fe)
Universitat Autònoma de Barcelona

Date:	2019
Abstract:	Progress in the understanding of many tumors has enabled the development of new therapies, such as those targeted at specific molecules involved in cell growth (targeted therapies) or intended to modulate the immune system (immunotherapy). However, along with the clinical benefit provided by these new treatments, new adverse effects have also appeared. Dermatological toxicities such as papulopustular eruptions, xerosis, and pruritus are common with EGFR inhibitors. Other adverse effects have also been described with PDGFR, BCR-ABL, and MAPK tyrosine kinase inhibitors, antiangiogenic drugs, and inhibitors at immune checkpoints such as CTLA-4 and PD-1/PD-L1. Onset of these adverse effects often causes dose reductions and/or delays in administering the prescribed therapy, which can affect patient survival and quality of life. It is, therefore, important to prevent the occurrence of these adverse effects, or to treat unavoidable ones as soon as possible. This requires cooperation between medical oncologists and dermatologists. This article reviews the various dermatological toxicities associated with targeted therapies and immunotherapies, along with their diagnosis and therapeutic management.
Rights:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original.
Language:	Anglès
Document:	Article ; recerca ; Versió publicada
Subject:	Anti-EGFR ; Antiangiogenic drugs ; Dermatological toxicity ; Immune checkpoint inhibitors ; MTOR inhibitors ; Targeted therapies
Published in:	Clinical & Translational Oncology, Vol. 21 Núm. 5 (january 2019) , p. 556-571, ISSN 1699-3055

DOI: 10.1007/s12094-018-1953-x
PMID: 30284232

16 p, 2.1 MB

The record appears in these collections:
Research literature > UAB research groups literature > Research Centres and Groups (research output) > Health sciences and biosciences > Institut de Recerca Sant Pau
Articles > Research articles
Articles > Published articles